135 related articles for article (PubMed ID: 2333780)
21. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.
Davis JR; Heath DA
Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920
[TBL] [Abstract][Full Text] [Related]
22. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.
Thiébaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P
Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129
[TBL] [Abstract][Full Text] [Related]
23. Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
Endo K; Katsumata K; Iguchi H; Kubodera N; Teramoto T; Ikeda K; Fujita T; Ogata E
J Bone Miner Res; 1998 Sep; 13(9):1378-83. PubMed ID: 9738509
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
van Breukelen FJ; Bijvoet OL; van Oosterom AT
Lancet; 1979 Apr; 1(8120):803-5. PubMed ID: 86043
[TBL] [Abstract][Full Text] [Related]
25. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia.
Ostenstad B; Andersen OK
Acta Oncol; 1992; 31(8):861-4. PubMed ID: 1290634
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD).
Grutters JC; Hermus AR; de Mulder PH; Beex LV
Breast Cancer Res Treat; 1993; 25(3):277-81. PubMed ID: 8369528
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B
Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630
[TBL] [Abstract][Full Text] [Related]
30. Intravenous pamidronic acid in hypercalcemia due to parathyroid carcinoma.
Vega EM; Mautalen CA
Medicina (B Aires); 1991; 51(2):106-10. PubMed ID: 1820495
[TBL] [Abstract][Full Text] [Related]
31. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
32. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.
Harinck HI; Bijvoet OL; Plantingh AS; Body JJ; Elte JW; Sleeboom HP; Wildiers J; Neijt JP
Am J Med; 1987 Jun; 82(6):1133-42. PubMed ID: 3300303
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
[TBL] [Abstract][Full Text] [Related]
34. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
[TBL] [Abstract][Full Text] [Related]
35. Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate.
Boudailliez BR; Pautard BJ; Sebert JL; Kremp O; Piussan CX
Pediatr Nephrol; 1990 Sep; 4(5):510-1. PubMed ID: 2242318
[TBL] [Abstract][Full Text] [Related]
36. [Pamidronate in the treatment of tumor-associated hypercalcemia].
Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
[TBL] [Abstract][Full Text] [Related]
37. Dichloromethylene diphosphonate action in hematologic and other malignancies.
Canfield RE; Siris ES; Jacobs TP
Bone; 1987; 8 Suppl 1():S57-62. PubMed ID: 2961356
[TBL] [Abstract][Full Text] [Related]
38. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia.
Ralston SH; Alzaid AA; Gallacher SJ; Gardner MD; Cowan RA; Boyle IT
Q J Med; 1988 Oct; 68(258):825-34. PubMed ID: 3268894
[TBL] [Abstract][Full Text] [Related]
39. Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions.
Culbert EC; Schfirin BS
Obstet Gynecol; 2006 Sep; 108(3 Pt 2):789-91. PubMed ID: 17018504
[TBL] [Abstract][Full Text] [Related]
40. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
Mannix KA; Carmichael J; Harris AL; Cantwell BM
Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
